A study analyzing Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients
Latest Information Update: 16 May 2024
At a glance
- Drugs Blinatumomab (Primary) ; Olverembatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 May 2024 According to an Ascentage Pharma media release, the company announced that the results from this study has been selected for Poster Presentations and to be presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024).
- 11 Jan 2024 New trial record
- 12 Dec 2023 First Results presented at the 65th American Society of Hematology Annual Meeting and Exposition